dx.doi.org/10.1002/hep.21505, hdl.handle.net/1765/35980
Erasmus MC: University Medical Center Rotterdam

Lukasiewicz, E, Hellstrand, K, Westin, J, Ferrari, C, Neumann, A.U, Pawlotsky, J-M, … Lagging, M. (2007). Predicting treatment outcome following 24 weeks peginterferon α-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at Day 0, Day 22, Day 29, and Week 6 [3]. Hepatology, 45(1), 258–259. doi:10.1002/hep.21505